СУЧАСНІ ПОГЛЯДИ НА МЕТАБОЛІЧНИЙ СИНДРОМ У ДІТЕЙ ТА ПІДЛІТКІВ
DOI:
https://doi.org/10.32782/2226-2008-2024-2-10Ключові слова:
метаболічний синдром, ожиріння, цукровий діабет, діти, підлітки, лікування метаболічного синдрому.Анотація
Історично метаболічний синдром виник як концепція, а не як діагноз, і протягом багатьох років описувався під кількома іншими назвами. Важко оцінити поширеність метаболічного синдрому у дітей, оскільки в його численних визначеннях використовувалося багато різних критеріїв. Управління з контролю за якістю харчових продуктів і медикаментів США (FDA) схвалило фармакотерапію для дітей і підлітків з ожирінням, яку слід розглянути після того, як програма інтенсивної зміни способу життя не допомогла знизити масу тіла, а саме ліраглудит та симаглутид. Необхідно звернути увагу практикуючих лікарів на те, що нині в Україні ліраглутид зареєстрований для дітей віком старше 12 років, а симаглютид – для використання у дорослих старше 18 років. Необхідно, щоб практикуючі лікарі будь-якої спеціальності виявляли пацієнтів групи ризику та надавали вказівки щодо профілактики та лікування метаболічного синдрому.
Посилання
Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United
States, 1988–1994. Through 2013–2014. JAMA. 2016; 315(21): 2292–2299. doi: 10.1001/jama.2016.6361.
Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among
US adults, 1999–2010. JAMA. 2012; 307(5): 491–497. doi: 10.1001/jama.2012.39.
Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease
years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007; 120(2): 340–345. doi: 10.1542/
peds.2006-1699.
Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and
type 2 diabetes mellitus 25 to 30 years later. J Pediatr. 2008; 152(2): 201–206. doi: 10.1016/j.jpeds.2007.09.010.
Wu YE, Zhang CL, Zhen Q. Metabolic syndrome in children (Review). Exp Ther Med. 2016; 12(4): 2390–2394. doi:
3892/etm.2016.3632.
Bhat RC, Santhosh T, Sudha KM. Metabolic syndrome: a comprehensive review. Int J Basic Clin Pharmacol. 2024; 13(1):
–183. doi: https://doi.org/10.18203/2319-2003.ijbcp20233913.
Kylin E. Studien ueber das Hypertonie-Hyperglyca “mie-Hyperurika” miesyndrom. Zentralblatt fuer Innere Medizin. 1923;
: 105–127.
Vague J. Sexual Differentiation, a Factor Affecting the Forms of Obesity. La Presse Médicale. 1947; 55: 339–340.
Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965; 1: 137.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12): 1595–607. doi:
2337/diab.37.12.1595.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch
Intern Med. 1989; 149(7): 1514–20. doi: 10.1001/archinte.149.7.1514.
Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance
syndrome (syndrome X). Diabetes. 1992; 41(6): 715–22. doi: 10.2337/diab.41.6.715.
Magge SN, Goodman E, Armstrong SC. The Metabolic Syndrome in Children and Adolescents: Shifting the Focus to
Cardiometabolic Risk Factor Clustering. Pediatrics. 2017; 140(2): e20171603. doi: 10.1542/peds.2017-1603.
Wittcopp C, Conroy R. Metabolic Syndrome in Children and Adolescents. Pediatr Rev. 2016; 37(5): 193–202. doi: 10.1542/
pir.2014-0095.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International
Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009; 120(16): 1640–5. doi: 10.1161/
CIRCULATIONAHA.109.192644.
Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by
exercise training. Compr Physiol. 2013; 3(1): 1–58. doi: 10.1002/cphy.c110062.
Panda PK. Metabolic Syndrome in Children: Definition, Risk Factors, Prevention and Management – A Brief Overview.
Pediatr Oncall J. 2019; 16: 67–72. doi: 10.7199/ped.oncall.2019.17.
Bitew ZW, Alemu A, Ayele EG, Tenaw Z, Alebel A, Worku T. Metabolic syndrome among children and adolescents in low
and middle income countries: a systematic review and meta-analysis. Diabetol Metab Syndr. 2020; 12: 93. doi: 10.1186/
s13098-020-00601-8.
Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents:
findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;
(8): 821–7. doi: 10.1001/archpedi.157.8.821.
Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome – a critical
look on the discrepancies between definitions and its clinical importance. Int J Obes (Lond). 2021; 45(1): 12–24. doi:
1038/s41366-020-00713-1.
Agudelo GM, Bedoya G, Estrada A, Patiño FA, Muñoz AM, Velásquez CM. Variations in the prevalence of metabolic
syndrome in adolescents according to different criteria used for diagnosis: which definition should be chosen for this age
group? Metab Syndr Relat Disord. 2014; 12(4): 202–9. doi: 10.1089/met.2013.0127.
Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab
Syndr Relat Disord. 2013; 11(2): 71–80. doi: 10.1089/met.2012.0122.
D’Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Curr
Probl Pediatr Adolesc Health Care. 2013; 43(5): 114–23. doi: 10.1016/j.cppeds.2013.02.004.
Privitera G, Spadaro L, Alagona C, et al. Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis
and metabolic syndrome components. Acta Diabetol. 2016; 53(3): 449–59. doi: 10.1007/s00592-015-0816-y.
Zhang J, Xiang L, Zhang B, Cheng Y. Endothelial dysfunction in normoglycaemic first-degree relatives of type 2 diabetes
mellitus complicated with hyperuricaemia. Diab Vasc Dis Res. 2017; 14(2): 88–93. doi: 10.1177/1479164116678158.
Fernández JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples
of African-American, European-American, and Mexican-American children and adolescents. J Pediatr. 2004; 145(4):
–44. doi: 10.1016/j.jpeds.2004.06.044.
Cong X, Liu S, Wang W, Ma J, Li J. Combined consideration of body mass index and waist circumference identifies obesity
patterns associated with risk of stroke in a Chinese prospective cohort study. BMC Public Health. 2022; 22(1): 347. doi:
1186/s12889-022-12756-2.
Steinfath M, Vogl S, Violet N, et al. Simple changes of individual studies can improve the reproducibility of the biomedical
scientific process as a whole. PLoS One. 2018; 13(9): e0202762. doi: 10.1371/journal.pone.0202762.
Khoury M, Manlhiot C, McCrindle BW. Role of the waist/height ratio in the cardiometabolic risk assessment of children
classified by body mass index. J Am Coll Cardiol. 2013; 62(8): 742–51. doi: 10.1016/j.jacc.2013.01.026.
Abaturov OE, Yur’eva LM, Velychko VI, ta in. Obesity and disorders of food behavior: diagnosis, prevention and therapy:
basic method. / Abaturov OE, Yur’eva LM, editors. Lviv: Vidavets Marchenko TV; 2021. 267 p.
Kavey RW. Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach. Curr Atheroscler
Rep. 2023; 25(5): 237–245. doi: 10.1007/s11883-023-01099-x.
Standards of Medical Care in Diabetes-2017: Summary of Revisions. Diabetes Care. 2017; 40 (Suppl 1): S4–S5. doi:
2337/dc17-S003.
Velychko VI, Lahoda DO, Kornovan GV, Bazhora YI. The role of family in treating obesity in children. Clinical decline.
Healthy child. 2023; 18(1). doi: http://dx.doi.org/10.22141/2224-0551.18.1.2023.1560.
Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Semin Liver Dis. 2018;
(1): 1–13. doi: 10.1055/s-0038-1627456.
Artyomenko VV, Velychko VI, Lahoda DO, Nastradina NM, Nitochko KO. Polycystic ovarian syndrome: competencies of a
family doctor. Reproductive endocrinology. 2023; 67(5): 63–67. doi: http://dx.doi.org/10.18370/2309-4117.2023.67.63-67.
Fu L, Xie N, Qu F, Zhou J, Wang F. The Association Between Polycystic Ovary Syndrome and Metabolic Syndrome in
Adolescents: a Systematic Review and Meta-analysis. Reprod Sci. 2023; 30(1): 28–40. doi: 10.1007/s43032-022-00864-8.
Codazzi V, Frontino G, Galimberti L, Giustina A, Petrelli A. Mechanisms and risk factors of metabolic syndrome in children
and adolescents. Endocrine. 2023 Dec 22. doi: 10.1007/s12020-023-03642-x.
Podeanu MA, Turcu-Stiolica A, Subțirelu MS, et al. C-Reactive Protein as a Marker of Inflammation in Children and
Adolescents with Metabolic Syndrome: A Systematic Review and Meta-Analysis. Biomedicines. 2023; 11(11): 2961. doi:
3390/biomedicines11112961.
Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent
overweight and obesity: summary report. Pediatrics. 2007; 120 (Suppl 4): S164–92. doi: 10.1542/peds.2007-2329C.
Velychko VI, Mankovsky BM, Lahoda DO, Danylchuk GO, Wenger YI. Treatment of excess body mass or obesity in children.
DOMC [Internet]. 2021 [cited 2024 ber. 22]; 6: 34–39. Available from: https://doms.org.ua/wp-content/uploads/2022/08/
DOMS_1_2022_full-for-net-3.pdf.
Johnston BC, Merdad R, Sherifali D, et al. Updating the Canadian clinical practice guideline for managing pediatric obesity:
a protocol. CMAJ Open. 2022; 10(1): E155-E164. doi: 10.9778/cmajo.20200289.
O’Hara V, Cuda S, Kharofa R, Censani M, Conroy R, Browne NT. Clinical review: Guide to pharmacological management
in pediatric obesity medicine. Obes Pillars. 2023; 6: 100066. doi: 10.1016/j.obpill.2023.100066.
Hoelscher DM, Kirk S, Ritchie L, Cunningham-Sabo L. Position of the Academy of Nutrition and Dietetics: interventions
for the prevention and treatment of pediatric overweight and obesity. J Acad Nutr Diet. 2013; 113(10): 1375–94. doi:
1016/j.jand.2013.08.004.
Rajjo T, Mohammed K, Alsawas M, et al. Treatment of Pediatric Obesity: An Umbrella Systematic Review. J Clin Endocrinol
Metab. 2017; 102(3): 763b75. doi: 10.1210/jc.2016-2574.
Gow ML, Ho M, Burrows TL, et al. Impact of dietary macronutrient distribution on BMI and cardiometabolic outcomes in
overweight and obese children and adolescents: a systematic review. Nutr Rev. 2014; 72(7): 453–70. doi: 10.1111/nure.12111.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society
Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102(3): 709–757. doi: 10.1210/jc.2016-2573.
Bremer AA, Auinger P, Byrd RS. Relationship between insulin resistance-associated metabolic parameters and anthropometric
measurements with sugar-sweetened beverage intake and physical activity levels in US adolescents: findings from the
–2004 National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2009; 163(4): 328–35. doi:
1001/archpediatrics.2009.21.
Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of Inflammatory Cytokines, Growth Factors and Adipokines in
Adipogenesis and Insulin Resistance. Inflammation. 2022; 45(1): 31–44. doi: 10.1007/s10753-021-01559-z.
Herouvi D, Paltoglou G, Soldatou A, Kalpia C, Karanasios S, Karavanaki K. Lifestyle and Pharmacological Interventions
and Treatment Indications for the Management of Obesity in Children and Adolescents. Children (Basel). 2023; 10(7): 1230.
doi: 10.3390/children10071230.
Singhal V, Sella AC, Malhotra S. Pharmacotherapy in pediatric obesity: current evidence and landscape. Curr Opin
Endocrinol Diabetes Obes. 2021; 28(1): 55–63. doi: 10.1097/MED.0000000000000587.
McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity
in children aged 18 years and younger. JAMA Pediatr. 2014; 168(2): 178–84. doi: 10.1001/jamapediatrics.2013.4200.
Bruemmer D. Obesity and Weight Loss in Adolescents. 2020. Available from: https://www.acc.org/Latest-in-Cardiology/
Articles/2020/08/19/08/06/Obesity-and-Weight-Loss-in-Adolescents (Last accessed: 26.02.2024).
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N
Engl J Med. 2019; 381(7): 637–646. doi: 10.1056/NEJMoa1903822.
Cornejo-Estrada A, Nieto-Rodríguez C, León-Figueroa DA, Moreno-Ramos E, Cabanillas-Ramirez C, Barboza JJ. Efficacy
of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled
Trials. Children (Basel). 2023; 10(2): 208. doi: 10.3390/children10020208.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with
Obesity. N Engl J Med. 2020; 382(22): 2117–2128. doi: 10.1056/NEJMoa1916038.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med.
; 387(24): 2245–2257. doi: 10.1056/NEJMoa2208601.
Krewson C. FDA approves semaglutide for obesity in adolescents. Available from: https://www.contemporarypediatrics.
com/view/fda-approves-semaglutide-for-obesity-in-adolescents (Last accessed: 26.02.2024).
Kansra AR, Lakkunarajah S, Jay MS. Childhood and Adolescent Obesity: A Review. Front Pediatr. 2021; 8: 581461. doi:
3389/fped.2020.581461.
Nobili V, Vajro P, Dezsofi A, et al. Indications and limitations of bariatric intervention in severely obese children and
adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. J Pediatr
Gastroenterol Nutr. 2015; 60(4): 550–61. doi: 10.1097/MPG.0000000000000715.
Schmoke N, Ogle S, Inge T. Adolescent Bariatric Surgery. In: Feingold KR, Anawalt B, Blackman MR, et al., editors.
Endotext [Internet]. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK575728/ (Last accessed: 26.02.2024).
Velychko VI, Yurchenko IV, Lahoda DO, Yurchenko YeI. Type 2 diabetes mellitus: epidemiology, complications and early
diagnosis. Odesa Medical Journal. 2023; 3: 76–83. doi: https://doi.org/10.32782/2226-2008-2023-3-14.
